Last reviewed · How we verify
Combination Ozurdex with Ranibizumab PRN
Combination Ozurdex with Ranibizumab PRN is a marketed treatment offered by Valley Retina Institute, leveraging the synergistic effects of both drugs for undisclosed primary indications. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The primary risk lies in the lack of disclosed revenue and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Combination Ozurdex with Ranibizumab PRN |
|---|---|
| Also known as | Dexamethasone and Lucentis |
| Sponsor | Valley Retina Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema (PHASE3)
- Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only. (NA)
- Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: